Evidence map›Paper›PMID 42068868›Full record

ReviewJournal of optometry

The evidentiary basis and challenges associated with studying the role of light damage on ocular health.

Billy R Hammond, John Buch

Abstract readReview
In one paragraph

Review in Journal of optometry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Billy R HammondVision Sciences Laboratory, Behavioral and Brain Sciences Program, University of Georgia, Athens, GA, USA. Electronic address: bhammond@uga.edu.
John BuchResearch & Development; Johnson & Johnson Vision Care Inc., Jacksonville, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interaction between light and the eye is both essential and potentially harmful. Light regulates ocular development, supports vision, and influences systemic physiology, yet it can also induce photochemical damage. Determining whether chronic exposure to high-energy visible (HEV) light contributes to age-related ocular disease remains challenging. Randomized clinical trials, the gold standard for medical evidence, are largely infeasible for exposures that are lifelong, ubiquitous, and potentially harmful. Instead, researchers rely on a spectrum of evidence, from cellular and animal models to case studies, cohort studies, and expert consensus, each with unique advantages and limitations. This review categorizes existing evidence according to study design, evaluates its strengths and weaknesses, and considers how converging findings might inform clinical practice. We conclude that while acute light injury is well established, the long-term impact of low-level HEV exposure remains largely and necessarily inferential. Definitive evidence is difficult to obtain but improvements in exposure assessment and integration across different categories of evidence have led to a cautious but reasonable conclusion on the potential harms of long-term exposure.

Indexed as

Eye DiseasesLightAnimalsBlue LightHumansBlue-light hazardHigh-energy visible lightLight exposure assessmentMacular degenerationRetinal aging

Identifiers

PMID42068868
PMCPMC13145375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.